{
  "first_published_at": "2009-07-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087969", 
  "title": "Mycophenolate mofetil: pure red cell aplasia", 
  "tags": "{\"parsed_therapeutic\": [\"immunosuppression-transplantation\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Immunosuppression and transplantation\"]}", 
  "_document_number": 252, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "immunosuppression-transplantation"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Mycophenolate mofetil: pure red cell aplasia</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: July 2009</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Dose reduction or discontinuation of mycophenolate mofetil should be considered in patients who develop pure red cell aplasia. Changes to treatment should be done only under specialist supervision to minimise the risk of graft rejection-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Mycophenolate mofetil (CellCept) is an immunosuppressant indicated in combination with ciclosporin and corticosteroids for prophylaxis of acute transplant rejection in adults receiving allogeneic renal, cardiac or hepatic transplants, and in children and adolescents (age 2&ndash;18 years) receiving renal transplants.</p><p>Up to April 2009, 41 cases of pure red cell aplasia had been reported worldwide in association with mycophenolate mofetil. Pure red cell aplasia is a type of anaemia in which there is a selective reduction of red blood cell precursors on bone-marrow examination. Some patients were also receiving other medicines that could have contributed to the development of pure red cell aplasia (eg, alemtuzumab, tacrolimus, azathioprine, and co-trimoxazole). In four cases dose reduction, and in 12 cases discontinuation, of mycophenolate mofetil led to resolution of the condition. The mechanism by which mycophenolate mofetil may cause pure red cell aplasia is unknown.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Dose reduction or discontinuation of mycophenolate mofetil should be considered in patients who develop pure red cell aplasia. Changes to treatment should be done only under specialist supervision to minimise the risk of graft rejection</li>\r\n\t\t\t</ul></div><p>Further information is available in a <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON049424\" target=\"_blank\" title=\"letter sent to healthcare professionals in June 2009\">letter sent to healthcare professionals in June 2009</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update July 2009, vol 2 issue 12: 8.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Mycophenolate mofetil (CellCept) is an immunosuppressant indicated in combination with ciclosporin and corticosteroids for prophylaxis of acute transplant rejection in adults receiving allogeneic renal, cardiac or hepatic transplants, and in children and adolescents (age 2&#8211;18 years) receiving renal transplants.</p><p>Up to April 2009, 41 cases of pure red cell aplasia had been reported worldwide in association with mycophenolate mofetil. Pure red cell aplasia is a type of anaemia in which there is a selective reduction of red blood cell precursors on bone-marrow examination. Some patients were also receiving other medicines that could have contributed to the development of pure red cell aplasia (eg, alemtuzumab, tacrolimus, azathioprine, and co-trimoxazole). In four cases dose reduction, and in 12 cases discontinuation, of mycophenolate mofetil led to resolution of the condition. The mechanism by which mycophenolate mofetil may cause pure red cell aplasia is unknown.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>Dose reduction or discontinuation of mycophenolate mofetil should be considered in patients who develop pure red cell aplasia. Changes to treatment should be done only under specialist supervision to minimise the risk of graft rejection</li>\r\n\t\t\t</ul></div><p>Further information is available in a <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON049424\" target=\"_blank\" title=\"letter sent to healthcare professionals in June 2009\">letter sent to healthcare professionals in June 2009</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update July 2009, vol 2 issue 12: 8.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2009-07-01", 
  "date_last_modified": "2010-08-11", 
  "_assets": [], 
  "_item_id": 252, 
  "summary": "", 
  "body": "Article date: July 2009\n\nMycophenolate mofetil (CellCept) is an immunosuppressant indicated in combination with ciclosporin and corticosteroids for prophylaxis of acute transplant rejection in adults receiving allogeneic renal, cardiac or hepatic transplants, and in children and adolescents (age 2–18 years) receiving renal transplants.\n\nUp to April 2009, 41 cases of pure red cell aplasia had been reported worldwide in association with mycophenolate mofetil. Pure red cell aplasia is a type of anaemia in which there is a selective reduction of red blood cell precursors on bone-marrow examination. Some patients were also receiving other medicines that could have contributed to the development of pure red cell aplasia (eg, alemtuzumab, tacrolimus, azathioprine, and co-trimoxazole). In four cases dose reduction, and in 12 cases discontinuation, of mycophenolate mofetil led to resolution of the condition. The mechanism by which mycophenolate mofetil may cause pure red cell aplasia is unknown.\n\nAdvice for healthcare professionals  \n  \n  * Dose reduction or discontinuation of mycophenolate mofetil should be considered in patients who develop pure red cell aplasia. Changes to treatment should be done only under specialist supervision to minimise the risk of graft rejection  \n  \nFurther information is available in a [letter sent to healthcare professionals in June 2009](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON049424)\n\n \n\nArticle citation: Drug Safety Update July 2009, vol 2 issue 12: 8.\n"
}